The FDA on Monday, October 26, approved Pfizer’s talazoparib (Talzenna) in combination with enzalutamide (Xtandi) for adults with metastatic prostate cancer that carries homologous recombination repair (HRR) gene mutations and is still sensitive to hormone therapy, according to the agency.
The mouthful on the label is “metastatic androgen pathway modulation-naïve or -sensitive,” abbreviated mAPMN/S. It’s also known as metastatic hormone-sensitive prostate cancer. In plain terms: the combination can now be used earlier, before the cancer stops responding to hormone-blocking drugs.
Background: where this fits
Most prostate cancers grow in response to androgens, male hormones such as testosterone. So the backbone of treatment for metastatic disease is androgen deprivation therapy (ADT), which shuts down hormone production, often paired with drugs like enzalutamide that block the androgen receptor.
That works for a while. Eventually many cancers learn to grow anyway, a stage called castration-resistant, and options narrow.
Talazoparib plus enzalutamide was first approved in the US in June 2023 for that later, resistant stage in patients with HRR mutations, Pfizer says. This approval moves it upstream, to men whose cancer has spread but still responds to hormone therapy.
How the drug works
Talazoparib is a PARP inhibitor. PARP is an enzyme cells use to fix damaged DNA. HRR genes, including the well-known BRCA1 and BRCA2, run a separate repair system.
Tumors with broken HRR genes lean heavily on PARP to survive. Block PARP too, and the cancer cells can’t fix their DNA and die, while healthy cells with working HRR genes mostly cope. Pfizer says talazoparib also “traps” PARP at the site of DNA damage, which adds to the effect.
That’s why the label requires a test. The drug is aimed at a genetic weakness, so it goes to patients whose tumors have it.
What the trial showed
The approval rests on TALAPRO-3 (NCT04821622), a randomized, double-blind, placebo-controlled trial of 599 patients with HRR gene-mutated disease. Everyone got enzalutamide plus continuous ADT. Half also got talazoparib; half got a placebo.
- Progression: median radiographic progression-free survival (time until scans show the cancer growing, or death) wasn’t reached in the talazoparib arm, versus 45.8 months with placebo.
- Hazard ratio: 0.48, meaning roughly a 52% lower risk of radiographic progression or death, with p<0.0001.
- Three years: Pfizer estimates 77% of patients on the combination were progression-free at three years.
- Survival: overall survival data were immature at the time of analysis.
Pfizer says the benefit was consistent in patients with BRCA and non-BRCA mutations. The results were presented at ASCO, the big annual cancer conference, in 2026 and published in The New England Journal of Medicine.
“In the TALAPRO-3 trial, clinical benefits were consistent for patients with BRCA and non-BRCA HRR gene mutations, addressing a long-standing unmet need – and reinforcing the importance of biomarker testing at the time of diagnosis,” said Neeraj Agarwal of Dana-Farber, the trial’s global lead investigator, in Pfizer’s release.
The skeptical read
The catch: “not reached” is good news, since it means the treated group hadn’t progressed enough to calculate a median. But progression-free survival is a stand-in. Immature survival data means we don’t yet know whether delaying progression translates into longer lives. Pfizer’s own forward-looking statements list “whether the TALAPRO-3 trial will meet the key secondary endpoint for overall survival” as a risk.
The primary endpoint was also assessed by investigators, not an independent central review, according to the FDA. That’s common, and the trial was double-blind, but it means the main result rests on the investigators’ own reads.
Then there’s the toll. In TALAPRO-3, severe (grade 3 or higher) anemia hit 51% of patients on the combination versus 3% on placebo, per Pfizer. Five percent stopped talazoparib because of it. Across Pfizer’s pooled prostate cancer data for the combination, 41% of patients needed a red blood cell transfusion.
Our read: a hazard ratio of 0.48 is a large relative effect on progression, though it doesn’t tell you how many more patients benefit in absolute terms, and Pfizer hasn’t published a three-year rate for the placebo arm. Pfizer argues that using targeted drugs earlier is where they can have the most impact. But this is a drug patients may take for years, starting at a stage when many feel well. Whether a large fraction needing transfusions is a fair trade will depend heavily on the survival data.
Who qualifies
Patients need an HRR mutation detected by an FDA-authorized test. The FDA had already approved Foundation Medicine’s FoundationOne CDx and FoundationOne Liquid CDx as companion diagnostics for this combination.
The trial tested 12 HRR genes: ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2 and RAD51C. Mutation status came from tumor tissue or circulating tumor DNA, fragments of tumor DNA found in a blood sample.
Pfizer cites research estimating that about 25% of patients with metastatic hormone-sensitive prostate cancer carry HRR mutations.
Why it matters: this is precision oncology working as designed, but it only works if patients get tested. If testing at diagnosis isn’t routine, eligible men will never be offered the drug.
The fine print
The recommended dose is 0.5 mg of talazoparib once daily alongside enzalutamide, until the disease progresses or side effects become unacceptable. Patients also need a GnRH analog, a hormone-suppressing injection, or to have had both testicles surgically removed.
The label carries warnings for myelodysplastic syndrome and acute myeloid leukemia (blood cancers that are rare but serious), myelosuppression (a drop in blood cell production) and embryo-fetal toxicity. Pfizer says monthly blood counts are recommended during treatment.
Regulatory notes
The application got priority review and was handled under Project Orbis, the FDA program for concurrent review with other regulators. Australia’s TGA and Health Canada are still reviewing. Pfizer says an application is also under review at the European Medicines Agency.
Who this affects
- Men with newly diagnosed metastatic prostate cancer: a new option, if their tumor has an HRR mutation and they get tested.
- Oncologists and urologists: more pressure to order genetic testing at diagnosis, not later.
- Pfizer: a bigger market for Talzenna, and for Xtandi, which Pfizer co-commercializes with Astellas in the US.
The takeaway
The takeaway: this approval moves a targeted drug into an earlier stage of the disease for patients with HRR mutations. The progression data are strong; the survival data aren’t in yet.
What to watch:
- TALAPRO-3 overall survival results.
- Decisions from the EMA, TGA and Health Canada.
- How widely HRR testing is used at diagnosis, since the approval only helps patients who get tested.
- Real-world data on anemia and transfusion rates outside the trial.
Update (Oct 29, 2026): we added the trial’s ClinicalTrials.gov record, made clear that the 52% figure is a relative reduction in risk, and attributed the view that targeted drugs work best when used earlier to Pfizer rather than stating it as fact. This story reports on a regulatory decision and is not medical advice.
Image: Otis Brawley (Photographer) / Wikimedia Commons, Public domain
.jpg){kind=link}